Prevention and therapy of anemia in tumor patients with Epoetin beta (NeoRecormon®);Prävention und therapie der anämie bei tumorpatienten mit Epoetin beta (NeoRecormon®)

Tumor Diagnostik und Therapie

Volumn 26, Issue 4, 2005, Pages 166-171

  Oberhoff, C ^a   Stauch, M ^a   Wilhelm, G ^a   Musch, E ^a   Heinrich, B ^a   Neise, M ^a   Grabenhorst, U ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anaemia; Epoetin beta; Erythropoietin; Fatigue; Haemoglobin; Pharmacovigilance study

Indexed keywords

GROWTH FACTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ERYTHROCYTE; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVARY CANCER; QUALITY OF LIFE; SIDE EFFECT;

EID: 24044553012     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858478     Document Type: Article

References (26)

1. Ludwig H, Fritz E. Incidence and clinical significance of anemia in malignant disease. In: Smyth JF, Boogaerts MA, Ehmer BRM. (eds). Erythropoietin in cancer supportive treatment. New York: Marcel Dekker, 1996:35-44
2. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28 (suppl 8): 1-6
3. Nowrousian MR, Kasper C, Oberhoff C et al. Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM. (eds). Erythropoietin in cancer supportive treatment. New York: Marcel Dekker, 1996: 13-34
4. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25 (suppl 7): 2-6
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634
6. Harrison L, Shasha D, Shiaova L et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001; 28 (suppl 8): 54-59
7. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28 (suppl 8): 7-14
8. Sobrero A, Puglisi F, Guglielmi A et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001; 28 (suppl 8): 15-23
9. Vaupel P, Kelleher DK. Tumor hypoxia. Stuttgart: WVG, 1999
10. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Role of hypoxia and anemia. Med Oncol 2001; 18: 243-259
11. Enke M. Correction of cancer anemia - impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie 2001; 24: 450-454
12. Blohmer JU, Wurschmidt F, Petry U et al. 6th interim analysis of a prospective, randomized, open and controlled AGO and NOGGO intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin aifa for patients with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003; 22: 1798
13. Bohlius J, Langensiepen S, Schwarzer G et al. On behalf of the Cochrane Hematological Malignancies Group. Does erythropoietin improve overall survival of patients with malignancies? Final analysis of a comprehensive meta-analysis. Onkologie 2003; 26: V276
14. Beguin Y. A risk-benefit assessment of epoetin in the management of anemia associated with cancer. Drug Saf 1998; 19: 269-282
15. Weinberg ED. Iron therapy and cancer. Kidney Int 1999; 55 (suppl 69): 131-134
16. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29 (suppl 2): 2-8
17. Rizzo JD, Lichtin AE, Woolf SH et al. Use of Epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of haematology. J Clin Oncol 2002; 20: 4083-4107
18. Cazzola M, Beguin Y, Kloczko J et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: 386-393
19. Osterborg A, Brandberg Y, Molostova V et al. Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-2494
20. Boogaerts M, Coiffier B, Kainz C. Epoetin B QOL Working Group. Impact of epoetin B on quality of life in patients with malignant disease. Br J Cancer 2003; 88: 988-995
21. Littlewood TJ, Bajetta E, Nortier JWR et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874
22. Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9: 255-260
23. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34 (suppl 2): 13-19
24. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life-scores. J Clin Oncol 1998; 16: 139-144
25. Caro JJ, Sala M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91: 2214-2221
26. Beguin Y. Soluble transferring receptor for the evaluation of erythropoiesis and iron status. Clinica Chimica Acta 2003; 329: 9-22